To develop scalable Adeno Associated Virus (AAV) production bioprocess
Swedish contract development and manufacturing organisation (CDMO) Cobra Biologics will work with Tecrea, a UK-based biotechnology company, to develop a scalable Adeno Associated Virus (AAV) production bioprocess.
The companies have been awarded a 15-month collaborative grant of £112,291 (US$166,000) by the UK’s innovation agency, Innovate UK.
The collaboration 'aims to achieve scalable GMP production of AAV at low cost' using NanoCargo, Tecrea's low toxicity nanoparticle-based transfection system and Cobra’s hollow fibre bioreactors, the companies said.
Dr Daniel Smith, CSO Cobra Biologics, said this project 'has the potential to expand our current viral production offering for AAV, providing a scalable route for viral vector production using a transient transfection approach'.
The grant is awarded under Innovate UK’s ‘Technology Inspired Innovation’ competition, which aims to stimulate innovation within biosciences.